High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis

References

• Joerger M, Huitema ADR, Illerhaus G, et al. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 2012;53:1867–1875.
   PubMed Web of Science ®Google Scholar
• Munzone E, Curigliano G, Burstein HJ, et al. CMF revisited in the 21st century. Ann Oncol 2012;23:305–311.
   PubMed Web of Science ®Google Scholar
• D’Adamo DR. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 2011;38:S19–S29.
   PubMed Web of Science ®Google Scholar
• Frei E 3rd, Blum RH, Pitman SW, et al. High dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity. Am J Med 1980;68:370–376.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100:2222–2232.
   PubMed Web of Science ®Google Scholar
• Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208–216.
   PubMed Web of Science ®Google Scholar
• Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667–1672.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004;90:353–358.
   PubMed Web of Science ®Google Scholar
• Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009;63:599–604.
   PubMed Web of Science ®Google Scholar
• de Miguel D, García-Suárez J, Martín Y, et al. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant 2008;23:3762–3766.
   PubMed Web of Science ®Google Scholar
• Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol 2002;13:327–330.
   PubMed Web of Science ®Google Scholar
• Dalle J-H, Auvrignon A, Vassal G, et al. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 2002;24: 321–322.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema ADR, van den Bongard HJGD, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006;62:71–80.
   PubMed Web of Science ®Google Scholar
• Santucci R, Levêque D, Lescoute A, et al. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res 2010;30:3807–3810.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009;67:44–49.
   PubMed Web of Science ®Google Scholar
• Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;302:666–671.
   PubMed Web of Science ®Google Scholar
• Widemann B, Adamson P. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11:694–703.
   PubMed Web of Science ®Google Scholar
• Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in united states veterans with diffuse large B-cell lymphoma. J Clin Oncol 2012;30:3217–3222.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03. [Internet]. NCI, NIH, DHHS. NIH publication #09-7473. 14 June 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results program. Cancer 2009;115:1531–1543.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Ito K, Oleschuk CJ, Westlake C, et al. Mutation of trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 2001;276:38108–38114.
   PubMed Web of Science ®Google Scholar
• Joannon P, Oviedo I, Campbell M, et al. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004;43:17–22.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2013;121:898–904.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64:5804–5811.
   PubMed Web of Science ®Google Scholar